Using mHealth Technologies for Case Finding in Tuberculosis and Other Infectious Diseases in Africa: Systematic Review.

Publication date: Aug 26, 2024

Mobile health (mHealth) technologies are increasingly used in contact tracing and case finding, enhancing and replacing traditional methods for managing infectious diseases such as Ebola, tuberculosis, COVID-19, and HIV. However, the variations in their development approaches, implementation scopes, and effectiveness introduce uncertainty regarding their potential to improve public health outcomes. We conducted this systematic review to explore how mHealth technologies are developed, implemented, and evaluated. We aimed to deepen our understanding of mHealth’s role in contact tracing, enhancing both the implementation and overall health outcomes. We searched and reviewed studies conducted in Africa focusing on tuberculosis, Ebola, HIV, and COVID-19 and published between 1990 and 2023 using the PubMed, Scopus, Web of Science, and Google Scholar databases. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to review, synthesize, and report the findings from articles that met our criteria. We identified 11,943 articles, but only 19 (0. 16%) met our criteria, revealing a large gap in technologies specifically aimed at case finding and contact tracing of infectious diseases. These technologies addressed a broad spectrum of diseases, with a predominant focus on Ebola and tuberculosis. The type of technologies used ranged from mobile data collection platforms and smartphone apps to advanced geographic information systems (GISs) and bidirectional communication systems. Technologies deployed in programmatic settings, often developed using design thinking frameworks, were backed by significant funding and often deployed at a large scale but frequently lacked rigorous evaluations. In contrast, technologies used in research settings, although providing more detailed evaluation of both technical performance and health outcomes, were constrained by scale and insufficient funding. These challenges not only prevented these technologies from being tested on a wider scale but also hindered their ability to provide actionable and generalizable insights that could inform public health policies effectively. Overall, this review underscored a need for organized development approaches and comprehensive evaluations. A significant gap exists between the expansive deployment of mHealth technologies in programmatic settings, which are typically well funded and rigorously developed, and the more robust evaluations necessary to ascertain their effectiveness. Future research should consider integrating the robust evaluations often found in research settings with the scale and developmental rigor of programmatic implementations. By embedding advanced research methodologies within programmatic frameworks at the design thinking stage, mHealth technologies can potentially become technically viable and effectively meet specific contact tracing health outcomes to inform policy effectively.

Open Access PDF

Concepts Keywords
Africa Africa
Databases Communicable Diseases
Google Contact Tracing
Tuberculosis contact tracing
COVID-19
COVID-19
design thinking
Ebola
Hemorrhagic Fever, Ebola
HIV
Humans
infectious diseases
mHealth
mobile health
mobile phone
Telemedicine
Tuberculosis
tuberculosis

Semantics

Type Source Name
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH Infectious Diseases
disease IDO contact tracing
disease MESH COVID-19
disease VO effectiveness
disease MESH uncertainty
disease VO report
drug DRUGBANK Methionine
disease VO Gap
disease VO viable
drug DRUGBANK Methylphenidate
drug DRUGBANK Spinosad
disease VO efficient
disease VO organization
disease IDO intervention
disease IDO process
disease VO inefficient
disease VO publication
disease IDO country
disease IDO facility
disease IDO blood
disease VO population
disease VO efficiency
disease MESH death
disease MESH cholera
disease MESH brucellosis
disease MESH impetigo
disease MESH Leprosy
disease VO leprosy vaccine
drug DRUGBANK Methyltestosterone
disease MESH emergency
disease VO document
disease VO storage
drug DRUGBANK Trestolone
drug DRUGBANK Huperzine B
drug DRUGBANK Etoperidone
drug DRUGBANK Tretamine
disease VO volume
disease VO Imovax ID
disease IDO developmental process
disease VO effective
disease VO pregnant women
disease MESH AIDS
disease MESH Ebola virus disease
disease MESH pulmonary tuberculosis
disease IDO assay
disease VO gene
disease IDO pathogen
disease MESH infection
disease IDO quality
drug DRUGBANK Coenzyme M
disease VO protocol
disease VO study design
disease IDO immunodeficiency
disease IDO production

Original Article

(Visited 1 times, 1 visits today)